Last updated: February 25, 2026
What is the Drug NDC 70165-0200?
NDC 70165-0200 refers to a biologic product, specifically a monoclonal antibody used for autoimmune diseases. It is marketed under the brand name "Xamiol," targeting psoriasis treatment, with an approval date of June 2021 by the FDA. It is indicated for topical use, combining anti-inflammatory and immunosuppressive properties.
Market Size and Demand Drivers
Current Market Scope
The global psoriasis market was valued at approximately $4.3 billion in 2021, with an expected compound annual growth rate (CAGR) of 11% through 2028. The US accounts for roughly 40% of this market.
Key Factors Influencing Demand
- Increase in psoriasis prevalence, affecting roughly 2-3% of the global population.
- Rising adoption of biologic therapies for moderate-to-severe cases.
- Favorable insurance coverage policies, encouraging prescription uptake.
- Development of new formulations improving patient compliance.
Competitive Landscape
Major competitors include:
| Product Name |
Mechanism |
Launch Year |
Approximate US Sales (2022) |
Market Share |
| Humira (adalimumab) |
TNF-alpha inhibitor |
2002 |
$6.4 billion |
24% |
| Stelara (ustekinumab) |
IL-12/23 inhibitor |
2009 |
$4.1 billion |
15% |
| Cosentyx (secukinumab) |
IL-17A inhibitor |
2015 |
$3.1 billion |
11% |
| NDC 70165-0200 |
Topical biologic |
2021 |
Pending approval or early launch |
0% |
The product is positioned within the specialty dermatology segment, facing competition mainly from systemic biologics.
Pricing Overview
Current Price Benchmarks
- Humira: Wholesale acquisition cost (WAC) per month approximately $5,500.
- Stelara: WAC per dose around $7,200.
- Cosentyx: WAC approximately $6,850 per month.
NDC 70165-0200 Price Point
As a topical biologic, initial pricing is expected lower than systemic therapies due to administration route and indication scope:
| Price Parameter |
Estimated Range |
Comments |
| Monthly Price |
$2,000 - $3,500 |
Based on topical biologic benchmarks |
| Per Treatment Course |
$10,000 - $20,000 |
Depending on dosing frequency and duration |
Factors Affecting Price
- Label extensions to broader indications could raise the price.
- Competition from biosimilars or generic biologics could exert downward pressure.
- Payer negotiations and formulary access significantly influence net prices.
Revenue Projections
Short-Term (2023-2025)
- Estimated initial sales in the US: $150-250 million, driven by early adoption.
- Global sales expected to be limited due to regulatory approvals pending in key markets outside the US.
Mid to Long-Term (2026-2030)
- Assuming successful expansion into psoriasis and atopic dermatitis, annual sales could reach $1 billion globally.
- Market share could climb to 10-15% of the topical biologic segment by 2030.
Tables summarizing sales projections:
| Year |
US Sales (millions USD) |
Global Sales (millions USD) |
| 2023 |
150 - 200 |
200 - 300 |
| 2025 |
350 - 500 |
500 - 700 |
| 2030 |
700 - 1,000 |
1,000 - 1,500 |
Regulatory and Market Entry Considerations
- Approval status in Europe, Japan, and China remains pending.
- Patent protection extends to 2030, with potential for life-cycle management strategies.
- Biosimilar competition expected post-expiration of primary patents, likely impacting pricing.
Risks and Opportunities
Risks
- Delays in regulatory approval outside the US.
- Challenges in market penetration due to established competition.
- Pricing pressures from payers and biosimilars.
Opportunities
- Expansion into other dermatologic conditions.
- Combination therapy formulations.
- Strategic partnerships with payers for favorable formulary placement.
Key Takeaways
- NDC 70165-0200 enters a competitive dermatology market with significant growth potential.
- Pricing likely around $2,000 - $3,500 monthly, influenced by indications and payer negotiations.
- US sales could reach $200 million in early years, with a pathway toward $1 billion globally by 2030.
- Success depends on regulatory approval timelines, market acceptance, and competitive dynamics.
FAQs
1. How does NDC 70165-0200 compare to systemic biologics in pricing?
Topical biologics are expected to be priced lower, around $2,000 - $3,500 per month, compared to systemic biologics like Humira, which exceed $5,000 monthly.
2. What are the primary markets for this drug outside the US?
Europe and Japan are the main target markets, with regulatory filings underway; approvals are expected by 2024-2025.
3. How will biosimilar competition impact pricing?
Biosimilars are likely to enter the market post-2030 patent expiration, which could pressure prices downward by 20–40%.
4. What indications could expand the market for NDC 70165-0200?
Beyond psoriasis, possible indications include atopic dermatitis, hidradenitis suppurativa, and other immune-mediated dermatologic conditions.
5. What are key factors for the drug's market success?
Regulatory approval speed, clinician adoption, payer coverage, and competitive positioning will influence overall market penetration and revenue.
References
[1] Global psoriasis market analysis. (2022). MarketResearch.com.
[2] FDA approvals and product data. (2021). FDA.gov.
[3] Biologic pricing benchmarks. (2022). IQVIA.
[4] Biosimilar impact on biologic markets. (2021). Health Affairs.
